Compare · COR vs MEDS
COR vs MEDS
Side-by-side comparison of Cencora Inc. (COR) and TRxADE HEALTH Inc. (MEDS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COR and MEDS operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- COR is the larger of the two at $63.07B, about 6448.4x MEDS ($9.8M).
- Over the past year, COR is down 2.0% and MEDS is down 94.4% - COR leads by 92.4 points.
- MEDS has been more active in the news (9 items in the past 4 weeks vs 5 for COR).
- COR has more recent analyst coverage (25 ratings vs 1 for MEDS).
- Company
- Cencora Inc.
- TRxADE HEALTH Inc.
- Price
- $330.99+0.12%
- $1.94-4.67%
- Market cap
- $63.07B
- $9.8M
- 1M return
- +6.82%
- -52.33%
- 1Y return
- -2.01%
- -94.43%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 9
- Recent ratings
- 25
- 1
Cencora Inc.
CoreSite Realty Corporation (NYSE:COR) delivers secure, reliable, high-performance data center, cloud access and interconnection solutions to a growing customer ecosystem across eight key North American markets. More than 1,375 of the world's leading enterprises, network operators, cloud providers, and supporting service providers choose CoreSite to connect, protect and optimize their performance-sensitive data, applications and computing workloads. Our scalable, flexible solutions and 460+ dedicated employees consistently deliver unmatched data center options  all of which leads to a best-in-class customer experience and lasting relationships.
TRxADE HEALTH Inc.
TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Land O' Lakes, Florida.
Latest COR
- Gabelli To Host 8th Annual Healthcare Symposium
- SEC Form 8-K filed by Cencora Inc.
- Cencora to Acquire American Oncology Network to Strengthen Support of Community Oncology
- SEC Form 4 filed by Cencora Inc.
- SEC Form 4 filed by Cencora Inc.
- Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release
- New insider Sanchez Robert E claimed ownership of 197 shares (SEC Form 3)
- Cencora Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Cencora Elects Robert E. Sanchez to Its Board of Directors
- Director Greenberg Lon R sold $411,264 worth of shares (1,280 units at $321.30), decreasing direct ownership by 7% to 17,128 units (SEC Form 4)
Latest MEDS
- DataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy Network
- Datavault AI Signs Non-Binding Letter of Intent to Acquire a 19.9% Equity Stake in DataMEDS AI in Consideration of an Expanded Technology License
- DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies
- DataMeds Regains Compliance With NASDAQ Listing Standards
- DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap
- DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform
- DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division
- DataMEDS SI Announces Helomics Receives Medicaid Coverage Policy For Chemofx(R) Assay In Gynecologic Cancers
- Datameds AI Files DBAs Datameds SI And Corexa Health SI And Reminds Shareholders Of Record As Of August 7, 2026 Of Dream Bowl Meme Coin I Payment
- These Stocks Roar into October with Fresh Catalysts